Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Next Previous
X
Search
Trial Profile

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IO102 IO103 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-D38
  • Sponsors IO Biotech

    • Most Recent Events

    • 13 Aug 2024 According to an IO Biotech media release, the Company plans to share updates from the NSCLC cohort, which also completed enrollment, at a medical meeting this fall.
    • 25 Jul 2024 According to an IO Biotech media release, data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort from this study has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 and will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.
    • 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top